logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience sees positive results from study using DehydraTECH Technology

Lexaria Bioscience (CSE:LXX-OTCQX:LXRP) President John Docherty joined Steve Darling from Proactive Investors Vancouver to talk about a recent controlled, double-blinded European human clinical study that evaluated TurboCBD, Lexaria’s  DehydraTECH powered, cannabidiol fortified hemp-oil capsule.

Docherty told Proactive the parameters of the study and some of the impressive results. He also discussed 2019 and what this study and potentially others will do for the company and their licensing of the technology. 

Quick facts: Lexaria Bioscience Corp.

Price: 0.59 CAD

CSE:LXX
Market: CSE
Market Cap: $47.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...

on 01/22/2020

2 min read